• Return to Headlines

Top 5 Companies in the Biotechnology Industry With the Lowest Debt-to-Capital Ratio (AST, NLNK, ACHN, ENTA, TGTX)

By Amy Schwartz

Below are the three companies in the Biotechnology industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Asterias Bio ranks lowest with a a Debt-to-Capital ratio of 6.4%. Following is Newlink Genetics with a a Debt-to-Capital ratio of 7.3%. Achillion Pharma ranks third lowest with a a Debt-to-Capital ratio of 9.3%.

Enanta Pharmaceu follows with a a Debt-to-Capital ratio of 15.2%, and Tg Therapeutics rounds out the bottom five with a a Debt-to-Capital ratio of 19.2%.

SmarTrend recommended that its subscribers protect gains by selling shares of Newlink Genetics on September 19th, 2017 by issuing a Downtrend alert when the shares were trading at $11.77. Since that call, shares of Newlink Genetics have fallen 62.0%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest debt-to-capital ratio amex:ast asterias bio newlink genetics achillion pharma enanta pharmaceu tg therapeutics

Ticker(s): NLNK ACHN ENTA TGTX